HIV possesses a remarkable capacity for mutational escape from therapeutics that target the viral proteins and enzymes. Inhibitory strategies aimed at highly conserved nucleic acid sequences within the genome are an attractive alternative. However, it has proven difficult to achieve an effective level of therapeutic at the appropriate site within the cell. Oligonucleotide delivery is a rapidly advancing field. We have investigated oligonucleotide analogues as steric-block therapeutics against two highly conserved regions of the HIV-1 genome. In the study we show that 2′O-methyl/locked nucleic acid oligonucleotides against the packaging signal and trans-activating response regions of HIV can inhibit replication of the virus.
ArrighiJFPionMWiznerowiczMGeijtenbeekTBGarciaEAbrahamSLeubaFDutoitVDucrey-RundquistOvan KooykYTronoD & PiguetV (2004) Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells. Journal of Virology78: 10848–10855.
2.
ArzumanovAStetsenkoDAMalakhovADReicheltSSorensenMDBabuBRWengelJ & GaitMJ (2003) A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2′-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2′-thio-LNA residues. Oligonucleotides13: 435–453.
3.
ArzumanovAWalshAPLiuXRajwanshiVKWengelJ & GaitMJ (2001a) Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction. Nucleosides Nucleotides Nucleic Acids20: 471–480.
4.
ArzumanovAWalshAPRajwanshiVKKumarRWengelJ & GaitMJ (2001b) Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides. Biochemistry40: 14645–14654.
5.
BodenDPuschOLeeFTuckerL & RamratnamB (2003) Human immunodeficiency virus type 1 escape from RNA interference. Journal of Virology77: 11531–11535.
6.
BondensgaardKPetersenMSinghSKRajwanshiVKKumarRWengelJ & JacobsenJP (2000) Structural studies of LNA:RNA duplexes by NMR: Conformations and implications for RNase H activity. Chemistry6: 2687–2695.
7.
BoulmeFFreundFMoreauSNielsenPEGryaznovSToulmeJJ & LitvakS. (1998) Modified (PNA, 2′-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV–1 reverse transcription. Nucleic Acids Research26: 5492–5500.
8.
BoulmeFPerala-HeapeMSarih-CottinL & LitvakS (1997) Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2. Biochimica et Biophysica Acta1351: 249–255.
9.
ChadwickDR & LeverAM (2000) Antisense RNA sequences targeting the 5′ leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. Gene Therapy7: 1362–1368.
10.
ChaubeyBTripathiSGangulySHarrisDCasaleRA & PandeyVN (2005) A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties. Virology331: 418–428.
11.
CleverJSassettiC & ParslowTG (1995) RNA secondary structure and binding sites for gag gene products in the 5′ packaging signal of human immunodeficiency virus type 1. Journal of Virology69: 2101–2109.
DarfeuilleFArzumanovAGryaznovSGaitMJDi PrimoC & ToulmeJJ (2002b) Loop-loop interaction of HIV-1 TAR RNA with N3′ —>P5′ deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proceedings of the National Academy of Sciences of the United States of America99: 9709–9714.
14.
DarfeuilleFHansenJBOrumHDi PrimoC & ToulmeJJ (2004) LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1. Nucleic Acids Research32: 3101–3107.
15.
DasATBrummelkampTRWesterhoutEMVinkMMadiredjoMBernardsR & BerkhoutB (2004) Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. Journal of Virology78: 2601–2605.
16.
DimitrovDS & BlumenthalR (1994) Photoinactivation and kinetics of membrane fusion mediated by the human immunodeficiency virus type 1 envelope glycoprotein. Journal of Virology68: 1956–1961.
17.
ElayadiANBraaschDA & CoreyDR (2002) Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry41: 9973–9981.
18.
HiratouTMiyano-KurosakiNGushimaH & TakakuH (2001) A new class of anti-HIV-1 oligonucleotide targeted to the polypurine tract of viral RNA. Nucleosides Nucleotides Nucleic Acids20: 715–718.
19.
HolmesSCArzumanovAA & GaitMJ (2003) Steric inhibition of human immunodeficiency virus type-1 Tat-dependent trans-activation in vitro and in cells by oligonucleotides containing 2′-O-methyl G-clamp ribonucleoside analogues. Nucleic Acids Research31: 2759–2768.
20.
HolmesSC & GaitMJ (2003) The synthesis of 2′-O-methyl G-clamp containing oligonucleotides and their inhibition of the HIV-1 Tat-TAR interaction. Nucleosides Nucleotides Nucleic Acids22: 1259–1262.
21.
IttigDLiuSRennebergDSchumperliD & LeumannCJ (2004) Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: A comparison of tricyclo-DNA with LNA. Nucleic Acids Research32: 346–353.
22.
JacqueJMTriquesK & StevensonM (2002) Modulation of HIV-1 replication by RNA interference. Nature418: 435–438.
23.
KaushikNBasuAPalumboPMyersRL & PandeyVN (2002) Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. Journal of Virology76: 3881–3891.
24.
KimptonJ & EmermanM (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galac-tosidase gene. Journal of Virology66: 2232–2239.
25.
LeeMTCoburnGAMcClureMO & CullenBR (2003) Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. Journal of Virology77: 11964–11972.
26.
LeedsJMHenrySPTruongLZutshiALevinAA & KornbrustD (1997) Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metabolism and Disposition25: 921–926.
27.
MarwickC (1998) First ‘antisense’ drug will treat CMV retinitis. Journal of the American Medical Association280: 871.
28.
MercatanteDRMohlerJL & KoleR (2002) Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and anti-neoplastic agents. The Journal of Biological Chemistry277: 49374–49382.
29.
MichelTMartinand-MariCDebartFLebleuBRobbinsI & VasseurJJ (2003) Cationic phosphoramidate alpha-oligonu-cleotides efficiently target single-stranded DNA and RNA and inhibit hepatitis C virus IRES-mediated translation. Nucleic Acids Research31: 5282–5290.
30.
ParkWSMiyano-KurosakiNAbeTTakaiKYamamotoN & TakakuH (2000) Inhibition of HIV-1 replication by a new type of circular dumbbell RNA/DNA chimeric oligonucleotides. Biochemical and Biophysical Research Communications270: 953–960.
31.
SeiSYangQEO'NeillDYoshimuraKNagashimaK & MitsuyaH (2000) Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. Journal of Virology74: 4621–4633.
32.
SierakowskaHSambadeMJAgrawalS & KoleR (1996) Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proceedings of the National Academy of Sciences of the United States of America93: 12840–12844.
33.
SteinCA (1999) Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Biochimica et bio-physica acta1489: 45–52.
34.
SuzukiJMiyano-KurosakiNKuwasakiTTakeuchiHKawaiG & TakakuH (2002) Inhibition of human immunodeficiency virus type 1 activity in vitro by a new self-stabilized oligonucleotide with guanosine-thymidine quadruplex motifs. Journal of Virology76: 3015–3022.
35.
WahlestedtCSalmiPGoodLKelaJJohnssonTHokfeltTBrobergerCPorrecaFLaiJRenKOssipovMKoshkinAJakobsenNSkouvJOerumHJacobsenMH & WengelJ. (2000) Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proceedings of the National Academy of Sciences of the United States of America97: 5633–5638.
36.
YamaguchiKPappBZhangDAliANAgrawalS & ByrnRA (1997) The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Research and Human Retroviruses13: 545–554.
37.
YoshinariKMiyagishiM & TairaK (2004) Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Research32: 691–699.
